Navigation Links
Positive Study Results for Ceftaroline Phase III Clinical Study for the Treatment of Complicated Skin and Skin Structure Infections Presented at ICAAC / IDSA
Date:10/27/2008

signed to achieve a non-inferiority margin of 10% for ceftaroline versus the comparator regimen for the above endpoints. The most common infections included deep, extensive cellulitis and major abscesses. The percent of patients with diabetes and peripheral vascular disease in the ceftaroline arm was 17.7% and 13.4%, respectively.(1) 30% of patients with a confirmed pathogen had a MRSA infection.

The most common pathogens isolated were S. aureus (MSSA and MRSA), Streptococcus pyogenes, Streptococcus agalactiae, Enterococcus faecalis, E. coli and P. aeruginosa. A comprehensive microbiological investigation was completed and ceftaroline demonstrated activity against a broad range of gram-positive pathogens and gram-negative pathogens. Microbiological eradication rates for ceftaroline alone were similar to those of the combination of vancomycin plus aztreonam (91.8% vs. 92.5%). MRSA eradication rates were also similar in the microbiologically evaluable patients in the ceftaroline and combination arms (94.9% vs. 91.8%).

"These new data add to the growing scientific evidence that support ceftaroline as a potential novel treatment for cSSSIs, including those caused by MRSA," said G. Ralph Corey, MD, Director, Infectious Diseases, Duke Clinical Research Institute. "These results are important because we see a growing number of infections, including many with difficult-to-treat organisms. Clearly new options are needed to optimize our current treatment capabilities."

The results of CANVAS I also demonstrate that ceftaroline was well tolerated. The majority of adverse events reported were mild and judged to be not treatment related. The percentage of patients who experienced an adverse event was similar in both treatment groups. The most common adverse events observed in the ceftaroline vs. vancomycin-plus-aztreonam arms were nausea (5.7% vs. 4.6%), headache (5.1% vs. 3.7%) and pruritis (3.1% vs. 8.4%).(1)

The data presented from CANVAS I demonstr
'/>"/>

SOURCE Forest Laboratories, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. Poniard Announces Positive Incremental Efficacy and Safety Data from Phase 2 Picoplatin Trial in Patients With Metastatic Colorectal Cancer
2. Poniard Announces Positive Incremental Efficacy and Safety Data From Ongoing Phase 2 Picoplatin Trial in Hormone-Refractory Prostate Cancer
3. Positive Preclinical Data on Cell Therapy for Spinal Disc Repair Presented at 23rd Annual Meeting of the North American Spine Society
4. Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure
5. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. Cepheid Receives FDA Clearance for First On-Demand Diagnostic Test for Life-Threatening MRSA and Staphylococcus aureus From Patient Positive Blood Cultures
8. Kuvan Receives Positive Opinion From CHMP for European Approval
9. InspireMD Announces Enrollment of First Patients in the MGuard(TM) Acute Myocardial Infarction Clinical Trial Data Will be Used to Confirm Initial Positive Results
10. Tengion Scientists Publish Positive Preclinical Findings With Neo-Organ Demonstrating Long-term Durability and Growth With Skeletal Maturation
11. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/28/2014)... The report provides qualitative insights on ... sub-segments of the market, in order to provide information ... rates and market sizes for each sub-segment of the ... growth. It also includes analysis of the company profiles ... the financial performances, product portfolios, and developments of each ...
(Date:11/27/2014)... The Europe Thermal Protective Clothing ... provide crucial revenue forecasts. It estimates the market ... a CAGR of 7.5%, from 2013 to 2018. ... Thermal Protective Clothing market report for a glimpse ... by various tables and figures. , http://www.micromarketmonitor.com/market/europe-thermal-protective-clothing-5957050557.html ...
(Date:11/27/2014)... -- Research and Markets  has announced ... Report 2014" report to their offering. ... Palmitic Acid Industry Report 2014 is a professional and ... palmitic acid industry. The report provides a ... and industry chain structure. The palmitic acid market analysis ...
(Date:11/27/2014)... Spartan Bioscience today announced that it ... Safety (MFDS) regulatory approval for its Spartan RX ... less than 60 minutes from a non-invasive cheek swab. ... for doctors to determine therapeutic strategies for drugs metabolized ... of the world’s most commonly prescribed drugs such as ...
Breaking Biology Technology:Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 2Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 3Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 4Glycomics Market by Application, Product & End-Users is estimated to reach $928.11 Million by 2019 - New Research Report by MarketsandMarkets 5The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 2The Europe Thermal Protective Clothing market is estimated to grow up to $577.9 million by 2018 - Report by MicroMarket Monitor 3Global Palmitic Acid Industry Report 2014 2Spartan Bioscience Receives Korean Regulatory Approval for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs 2Spartan Bioscience Receives Korean Regulatory Approval for First Rapid DNA Test of Mutations Affecting Metabolism of Common Drugs 3
... of Ablation Therapy Using HALO System Demonstrated for, ... Progression, SAN DIEGO, May 19 Booth ... a technology leader in the design and manufacture,of ... presentation,of a landmark study entitled, "A Randomized, Multicenter, ...
... size allows for treatment of smaller-diameter diseased saphenous vein ... ... Boston Scientific,Corporation (NYSE: BSX ) today announced the launch of its ... designed to contain,and remove embolic material that may be dislodged during an ...
... 19 /Xinhua-PRNewswire-FirstCall/ -- 3SBio Inc.,(Nasdaq: SSRX ), ... and marketing biopharmaceutical products,primarily in China, will present ... in New York on Thursday, May 22, 2008 ... webcast live and can be accessed on the,Webcasts ...
Cached Biology Technology:Presentation of Landmark Clinical Trial Evaluating Endoscopic Treatment for Pre-cancerous Condition of Esophagus 2Presentation of Landmark Clinical Trial Evaluating Endoscopic Treatment for Pre-cancerous Condition of Esophagus 3Boston Scientific Announces Launch of Expanded Size Range of FilterWire EZ(TM) Embolic Protection System 2Boston Scientific Announces Launch of Expanded Size Range of FilterWire EZ(TM) Embolic Protection System 3Boston Scientific Announces Launch of Expanded Size Range of FilterWire EZ(TM) Embolic Protection System 4
(Date:11/21/2014)... , November 18, 2014 According ... Market by Systems (Video, RFID, Access Control, Intrusion Detection, ... Hotels, Banks, Government), Component Service Geography - Global Forecasts ... Market is projected to be around $25 Billion in ... 2020, growing at a CAGR of 8.69%. ...
(Date:11/21/2014)... -- Earlier this year Donald Spector , Chairman of ... the most prolific inventors in the world, got a ... to third party agencies. Spector envisioned this technology even ... earliest known patents in this area. Now major technology ... care, elder care and hospital applications. This technology has ...
(Date:11/21/2014)... , Nov. 20, 2014 Strict laws ... efficiency are piloting the North American and European automotive ... accidents growing, gesture recognition systems that are intuitive and ... mark in the industry. New analysis ... Gesture Recognition Market in Europe ...
Breaking Biology News(10 mins):Industrial Security Systems Market Worth $38 Billion by 2020 2Industrial Security Systems Market Worth $38 Billion by 2020 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 2Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 3Patented Biosensor Wearable Technology Provides a More Civilized Method of Quarantine 4Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 2Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 3Gesture Recognition Intensifies with the Rise of In-car Smartphone Integration, Says Frost & Sullivan 4
... computation of haplotypes provides insight into genetic basis of ... map of genetic variation which can give clues to ... technologies collect genotypes, or information from the individual's ... to the variations between individuals' DNA at the level ...
... figured out the fate of healthy protein when it ... yeast: The protein converts to the prion form, rendering ... , This quick-change "mating" maneuver sheds important light on ... cause fatal brain ailments such as mad cow disease ...
... virus in tissues from patients who died of a ... the strain of virus in the measles vaccine caused ... issue of The Journal of Infectious Diseases, now available ... many more cases of the disease, known as subacute ...
Cached Biology News:U-M scientists say fused genes trigger the development of prostate cancer 2U-M scientists say fused genes trigger the development of prostate cancer 3U-M scientists say fused genes trigger the development of prostate cancer 4Prions rapidly 'remodel' good protein into bad, Brown study shows 2New study shows measles immunization may prevent fatal brain infection 2